Trimebutine
| Evidence Level: L3 | Predicted Indications: 2 |
Table of Contents
- Trimebutine
- Pharmacist Assessment Report
- Trimebutine: From Functional Gastrointestinal Disorders to Migraine Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Trimebutine: From Functional Gastrointestinal Disorders to Migraine Disorder
One-Sentence Summary
Trimebutine is a gut-acting opioid-receptor modulator that is marketed in Canada. The data compiled for this report do not list its approved indication. The TxGNN model predicts it may be useful for migraine disorder, mainly as an add-on to oral triptans. Evidence is limited to 0 registered clinical trials and 3 publications (including 1 randomized crossover trial).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the compiled Health Canada licence data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9964 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, trimebutine acts on mu, delta and kappa opioid receptors in the gut and modulates peripheral ion channels and gastrointestinal motility. This is inferred from general knowledge, not from the provided record.
Two routes could link it to migraine. The first is modulation of visceral and peripheral pain signalling, possibly including trigeminovascular pathways. The second is better gastric motility. Gastroparesis is common during migraine attacks and can delay absorption of oral triptans, so a prokinetic could help them work sooner and more consistently. The one controlled study found (2006) tested rizatriptan with and without trimebutine, which fits this second route better than a direct anti-migraine effect.
The very high TxGNN score is a computational prediction, not clinical evidence.
A second predicted indication, migraine with brainstem aura (score 0.9954), has no direct evidence. Its score most likely reflects its close relationship to migraine disorder. Triptans are traditionally used with caution in this subtype, which weakens the adjunct rationale further. It is not evaluated further here (Evidence Level L5, Hold).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16776704 | 2006 | RCT | Cephalalgia | Double-blind, randomized, crossover, placebo-controlled study of rizatriptan vs. rizatriptan plus trimebutine for acute migraine. The rationale was that adding a gastrokinetic could offset migraine-related gastroparesis. |
| 19220673 | 2009 | Review | J Gastroenterol Hepatol | Review of prokinetic agents for diseases outside the GI tract, including central nervous system conditions. |
| 16245431 | 2005 | Case report | Pol Merkur Lekarski | A 9-year-old girl with abdominal migraine did not respond to drotaverine, mebeverine or trimebutine. This is not supportive of efficacy. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02245664 | APO-TRIMEBUTINE | Not specified | Not specified |
| 02245663 | APO-TRIMEBUTINE | Not specified | Not specified |
| 02538202 | MINT-TRIMEBUTINE | Not specified | Not specified |
| 02538210 | MINT-TRIMEBUTINE | Not specified | Not specified |
All four licences are valid single-ingredient products.
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications or drug-interaction records were available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The only controlled evidence is one small crossover RCT of trimebutine added to a triptan, and the abstract provided does not show its results. The remaining literature is a general review and a case report that does not support efficacy. There are no registered trials. Safety data and the mechanism of action are also missing, so the 0.9964 TxGNN score cannot be treated as support on its own.
To proceed, the following is needed:
- Full text and results of the 2006 rizatriptan ± trimebutine RCT, with a check for replication
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Approved indications and dosage forms for the four Canadian licences
- Mechanism of action data from DrugBank to support the proposed links
- A defined hypothesis (adjunct to triptans vs. direct anti-migraine effect), followed by a pilot trial if the evidence supports it
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.